Mind Medicine (also known as MindMed) was the first psychedelic drugmaker to conduct an preliminary public offering (IPO), on Canada’s NEO Exchange in March 2020. The company had been founded lower than a 12 months earlier, in May 2019. The drugmaker is currently conducting two part three studies evaluating COMP360 in treatment-resistant despair. Results fro...